Parallax Volatility Advisers’s PTC Therapeutics PTCT Stock Holding History

Parallax Volatility Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-45,000	Closed	-$1.24M	–	2249
2023 Q4	$1.24M	Hold	45,000	–	–	﹤0.01%	1334
2023 Q3	$1.01M	Buy	+45,000	New	+$1.67M	﹤0.01%	1365
2023 Q1	–	Sell	-70,000	Closed	-$2.67M	–	3086
2022 Q4	$2.67M	Buy	+70,000	New	+$2.91M	﹤0.01%	1289
2018 Q3	–	Sell	-60,000	Closed	-$2.02M	–	3350
2018 Q2	$2.02M	Sell	60,000 -115,000	-66%	-$3.59M	﹤0.01%	897
2018 Q1	$4.74M	Buy	+175,000	New	+$4.43M	0.01%	534
2016 Q2	–	Sell	-30,000	Closed	-$193K	–	3285
2016 Q1	$193K	Sell	30,000 -40,000	-57%	-$694K	﹤0.01%	1770
2015 Q4	$2.27M	Buy	+70,000	New	+$2.06M	﹤0.01%	978

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's PTCT Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of PTC Therapeutics (PTCT) in Q1 2023, closing a stake of 12,764 shares — an estimated $487K sold.

Parallax Volatility Advisers first reported a position in PTCT in Q2 2017 and held it in 5 quarters. The position peaked at $10.6M in Q4 2017. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2023.

Parallax Volatility Advisers reported no remaining PTC Therapeutics position as of Q1 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 12,764 PTC Therapeutics shares in Q1 2023, an estimated $487K.
Parallax Volatility Advisers first reported a position in PTC Therapeutics in Q2 2017 and held it in 5 quarters.
Parallax Volatility Advisers's PTC Therapeutics position peaked at $10.6M in Q4 2017.
202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.